Please assess the completion status of the following clinical trial:

Trial Title: Progesterone for the Treatment of COVID-19 in Hospitalized Men

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Laboratory-confirmed COVID-19 with in 72 hours prior to randomization~2. Respiratory symptoms or abnormal lung exam or abnormal chest imaging AND oxygen saturation ≤94% on room air, or requiring supplemental oxygen less than 50% high flow~3. Understands and agrees to comply with planned study procedures~4. Agrees to the collection of venous blood per protocol~5. Must agree to be placed on prophylactic dose of anticoagulation for prevention of deep venous thrombosis (DVT) while hospitalized~Exclusion Criteria:~1. ALT or AST \>5 times the upper limit of normal~2. History of blood clots~3. History of breast cancer~4. Allergy to progesterone or betacyclodextrin~5. Use of supplemental oxygen prior to hospital admission~6. Requiring higher than 50% supplemental oxygen by high flow nasal cannula or mechanical ventilation

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Progesterone plus SOC (Type: EXPERIMENTAL): Progesterone 100 mg will be administered subcutaneously twice daily for 5 days in addition to institutional standard of care
- SOC only (Type: NO_INTERVENTION): Subjects will receive institutional standard of care only

Based on this trial design, predict the completion outcome and termination type (if applicable).